PureIMS receives a grant of € 41.028,58 to initiate the development of a new dry powder inhaler (DPI). This new DPI will contain an innovative dispersion mechanism to enable delivery of medicines such as antibiotics, vaccines, and biologics. Unlike current devices, it will be user-friendly and suitable for vulnerable groups like children and elderly […]
Full paper: Pharmaceutics 2025, 17(9), 1149; https://doi.org/10.3390/pharmaceutics17091149 Background/Objectives: The pulmonary administration of levodopa enables a rapid absorption and onset of action, making it a suitable administration route for managing OFF episodes in Parkinson’s disease. Currently, one dry powder product for inhalation (Inbrija) is available on the market, while another (Levodopa Cyclops) is in development. These […]
Please check out our latest poster on Epinephrine Cyclops® for GAFA 2025! GAFA 2025 is a medical conference on food allergy and anaphylaxis in Padua, Italy from 11–13 September 2025 and Jaap Wieling will attend this conference. Interested? Contact Jaap (jwieling@pureims.com)!
EMA as well as FDA recently designated PureIMS’s colistin dry powder inhaler ‘Colistin Cyclops®’ orphan drug product for the treatment of cystic fibrosis. Colistin Cyclops® is an orally inhaled antibiotic used for treating (chronic) Pseudomonas aeruginosa infections of the lungs. Despite the transformative potential of CFTR modulators in addressing the root causes of cystic fibrosis, […]
Fagron and PureIMS have joined forces to make CYCLOPS® dry powder inhaler available nationwide in the Netherlands. The two Dutch pharmaceutical companies recently signed an agreement, granting Fagron the exclusive rights to organize the national distribution of PureIMS’s compounded preparations, such as an inhaled antibiotic for the treatment of pulmonary Pseudomonas aeruginosa infections caused by […]
Please check out our latest poster (#708) presenting clinical study results of a head-to-head comparison between Levodopa Cyclops® and Inbrija®. Highlights are: Levodopa Cyclops® is safe and very well tolerated (no cough). Levodopa absorption from Cyclops® is comparable to Inbrija®, thereby, fulfilling the bioequivalence criteria. Results enable abbreviated registration routes with a limited – PK-only […]
Dry powder inhalers for rescue applications Check out this fascinating article on the potential of Cyclops® for rescue applications, featured in the Inhalation Technology Supplement of the PMPS Spring 2024 edition. Dive into the details through the link below. Don’t miss it!
Roden, the Netherlands, January 18, 2024 PureIMS, a pharmaceutical company focused on the development of innovative inhalation products, this week reported it has completed a comparative pharmacokinetic study with Levodopa Cyclops®. The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. These properties make Levodopa Cyclops® a prime candidate […]
Tuesday September 26 was an exciting day for the PureIMS team. Not only was the first cohort of volunteers dosed in the penultimate Levodopa Cyclops™ bioavailability study, we were also honored with the LIFE Science Innovation Award. LIFE Cooperative, very successfully organizing their annual conference and award ceremony, is a cooperation of 50+ LifeScience and MedTech SMEs […]
Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com
